SG10201503450WA - Vaccine against beta-herpesvirus infection and use thereof - Google Patents

Vaccine against beta-herpesvirus infection and use thereof

Info

Publication number
SG10201503450WA
SG10201503450WA SG10201503450WA SG10201503450WA SG10201503450WA SG 10201503450W A SG10201503450W A SG 10201503450WA SG 10201503450W A SG10201503450W A SG 10201503450WA SG 10201503450W A SG10201503450W A SG 10201503450WA SG 10201503450W A SG10201503450W A SG 10201503450WA
Authority
SG
Singapore
Prior art keywords
vaccine against
herpesvirus infection
against beta
beta
herpesvirus
Prior art date
Application number
SG10201503450WA
Inventor
Thirion Christian
Koszinowski Ulrich
A Mohr Christian
Ruzsics Zsolt
Original Assignee
Thirion Christian
Koszinowski Ulrich
A Mohr Christian
Ruzsics Zsolt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thirion Christian, Koszinowski Ulrich, A Mohr Christian, Ruzsics Zsolt filed Critical Thirion Christian
Publication of SG10201503450WA publication Critical patent/SG10201503450WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C12N2710/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201503450WA 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof SG10201503450WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004751 2010-05-05
EP10005045 2010-05-12

Publications (1)

Publication Number Publication Date
SG10201503450WA true SG10201503450WA (en) 2015-06-29

Family

ID=44146744

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012080891A SG185121A1 (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof
SG10201503450WA SG10201503450WA (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012080891A SG185121A1 (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof

Country Status (8)

Country Link
US (3) US9078867B2 (en)
EP (1) EP2566957B8 (en)
JP (2) JP2013527758A (en)
AU (1) AU2011250191A1 (en)
CA (2) CA3128572C (en)
ES (1) ES2679245T3 (en)
SG (2) SG185121A1 (en)
WO (1) WO2011138040A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
HUE037227T2 (en) 2010-05-14 2018-08-28 Univ Oregon Health & Science Recombinant HCMV and RHCMV vectors and uses thereof
PL2691530T3 (en) 2011-06-10 2019-02-28 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
AU2014225886B2 (en) * 2013-03-05 2020-04-16 Oregon Health & Science University Cytomegalovirus vectors enabling control of T cell targeting
AU2014344807A1 (en) 2013-10-29 2016-05-19 The University Of Sydney CMV immuno-stimulatory composition
UA120938C2 (en) 2014-07-16 2020-03-10 Орегон Хелс Енд Сайєнс Юніверсіті Human cytomegalovirus comprising exogenous antigens
MA41756A (en) 2015-02-10 2017-12-20 Fruh Klaus METHODS AND COMPOSITIONS USEFUL IN GENERATING NON-CANONIC CD8 + T LYMPHOCYTES RESPONSES
CA3005136A1 (en) 2015-11-20 2017-05-26 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
BR112019007982A2 (en) 2016-10-18 2019-07-02 Univ Oregon Health & Science cytomegalovirus vectors eliciting t cells restricted by histocompatibility complex molecules and major
WO2020014222A2 (en) * 2018-07-09 2020-01-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Viral promoters and compositions and methods of use thereof
US20230364215A1 (en) * 2020-10-02 2023-11-16 Colorado State University Research Foundation Compositions comprising inactivated microbes, and methods for use and production thereof
CN116042526B (en) * 2022-07-04 2023-11-10 北京肿瘤医院(北京大学肿瘤医院) Normal human immortalized colon fibroblasts with P16 gene specific methylation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374768B1 (en) 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
DE19733364A1 (en) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Method of cloning a large virus genome
US6573090B1 (en) 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
WO2005012545A2 (en) * 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
CA2567597C (en) * 2004-05-25 2014-03-18 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors

Also Published As

Publication number Publication date
CA3128572A1 (en) 2011-11-10
WO2011138040A8 (en) 2012-12-20
JP6427514B2 (en) 2018-11-21
EP2566957B1 (en) 2018-04-18
CA2798214C (en) 2021-10-19
JP2013527758A (en) 2013-07-04
US9078867B2 (en) 2015-07-14
WO2011138040A2 (en) 2011-11-10
US10842863B2 (en) 2020-11-24
CA2798214A1 (en) 2011-11-10
JP2016136950A (en) 2016-08-04
SG185121A1 (en) 2012-11-29
CA3128572C (en) 2023-02-21
US20190117766A1 (en) 2019-04-25
US20130202638A1 (en) 2013-08-08
AU2011250191A1 (en) 2012-11-22
WO2011138040A3 (en) 2012-10-26
US20150306210A1 (en) 2015-10-29
EP2566957B8 (en) 2018-06-06
ES2679245T3 (en) 2018-08-23
EP2566957A2 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
HUS2100032I1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
SG10201503450WA (en) Vaccine against beta-herpesvirus infection and use thereof
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
IL215389A0 (en) Pneumococcal vaccine and uses thereof
EP2552479A4 (en) Influenza virus vaccines and uses thereof
ZA201209411B (en) Vaccine and methods to reduce campylobacter infection
HRP20182083T1 (en) Novel combination and use
PL2521445T3 (en) Formulation and use thereof
PT2563806E (en) Human leukolectins and uses thereof
EP2581099A4 (en) Intervention medical device and preparation thereof
HK1184779A1 (en) Novel compound and medical use thereof
GB201006479D0 (en) Garment and use thereof
EP2650292A4 (en) Thiazolamine derivative and use thereof as anti-picornaviral infection medicament
GB201008286D0 (en) Device and use
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
EP2657236A4 (en) Novel 2-alkynyl-n9-propargyladenine and medicinal use thereof
GB201006380D0 (en) Excipients and their use
GB201012283D0 (en) Vaccine
GB201007588D0 (en) Vaccine
GB201007589D0 (en) Vaccine